Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

A total of 31 adult patients with AML entered in the EORTC/GIMEMA AML-10 trial, who received autologous stem cell transplantation (ASCT) after induction and consolidation chemotherapy, were prospectively evaluated for minimal residual disease (MRD) by multidimensional flow cytometry (MFC). Using a c...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia 2003-11, Vol.17 (11), p.2178-2182
Hauptverfasser:	VENDITTI, A, MAURILLO, L, PICARDI, A, FRANCHI, A, COCO, F. L, AMADORI, S, BUCCISANO, F, DEL POETA, G, MAZZONE, C, TAMBURINI, A, DEL PRINCIPE, M. I, CONSALVO, Ml, DE FABRITIIS, P, CUDILLO, L
Format:	Artikel
Sprache:	eng
Schlagworte:	Acute Disease Acute myeloid leukemia Adult Antineoplastic Combined Chemotherapy Protocols - therapeutic use Autografts Biological and medical sciences Chemotherapy Combined Modality Therapy Etoposide - administration & dosage Female Flow cytometry Hematologic and hematopoietic diseases Humans Idarubicin - administration & dosage Immunophenotyping Leukemia Leukemia, Myeloid - drug therapy Leukemia, Myeloid - mortality Leukemia, Myeloid - therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Leukocyte Count Longitudinal Studies Male Medical sciences Middle Aged Minimal residual disease Mitoxantrone - administration & dosage Multivariate analysis Neoplasm, Residual - diagnosis Patients Predictive Value of Tests Probability Recurrence Remission Risk Assessment Risk groups Stem Cell Transplantation Stem cells Survival Analysis Time Factors Transplantation Transplantation, Autologous Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!